Skip to main content
Premium Trial:

Request an Annual Quote

Sirius Collaborates with Parisian Hospitals

NEW YORK (GenomeWeb News) – Sirius Genomics will work with the Assistance Publique-Hopitaux de Paris (AP-HP) to study genomic markers for severe sepsis under a collaborative agreement, the company said today.

Sirius will work with the hospital system's Clinical Research and Development Department in a program aimed at developing a pharmacogenomic diagnostic to assess the responsiveness of severe sepsis patients to recombinant human activated Protein C, which is sold by Eli Lilly under the trade name Xigris.

"Access to AP-HP's severe sepsis patients will be critical in the validation of Sirius' sepsis biomarkers," Sirius President and CEO Brad Popovich said in a statement.

AP-HP is a public health system that includes 37 hospitals and undertakes an array of activities beyond healthcare, including research, health education, home nursing, teaching, and others.

Financial terms of the agreement were not disclosed.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.